Four decisions for medical devices and IVD tests from the meeting of the Norwegian Decision Forum on introduction of innovations in September

02

Oct 2017

Norway established in 2013 a framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. This framework is called the “New Method”.

In this framework, all innovations should undergo HTA before being funded. Selection of methods is performed by the Ordering Forum (Bestillerforum). If the method is of national concern, it undergoes Single Technology Appraisal at national level followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum). Decision Forum has regular meetings to review results of assessments to the make funding decisions.

On 25th of September, the Norwegian Decision Forum of “New Methods” had a meeting to review several medical technologies and IVD tests. Decisions were made in relation to the introduction of 2 new newborn screening tests, prehospital emergency thoracotomy, aortic valve replacement using sutureless stent Perceval, and digital breast tomosynthesis.

 

Two additional newborn screening IVD tests

In August 2017, the Order Forum of “New Method” requested the Norwegian Institute of Public Health (NIPH) in collaboration with the expert group to perform a rapid assessment of the extension of National Service for Screening of Newborns regarding two screening tests for rare diseases:

  • Severe combined immune deficiency (SCID) – using TREC (T-Cell Receptor Excision Circles) test
  • HMG-CoA lyase deficiency – using mass spectrometry

A systematic literature review was performed within rapid assessment (see the full report here). In accordance with the conclusion of this assessment HMG and SCID tests were considered suitable for inclusion into the program. Additionally, it was stated that implementation of the test of HMG involves very few changes in clinical practice. In the same time, TREC test can be performed within PCR procedure. Studies from other countries have shown that earlier diagnosis with SCID allows patients to receive earlier treatment that can lead to lower costs of healthcare services. Health economics studies demonstrated low overall cost for introducing of newborn screening of SCID via TREC test.

Thus, based on the report of rapid assessment the Decision Forum asked the Directorate of Health to clarify the extension of the newborn screening program with these methods as soon as possible (see full decision here).

 

Prehospital emergency thoracotomy

A negative decision was released for prehospital emergency thoracotomy in patients with cardiac arrest. This method was not recommended for the national method assessment due to limited evidence. It was noted that this procedure requires a high level of competence of medical staff who need regular experience in using this method. Additionally, there are about 10 patients per year which might require this procedure in Norway. However, professionals considered the need for further follow-up for this technology within “New Method” program in the future (see full decision here)

 

Aortic valve replacement using sutureless stent Perceval

In October of 2015, the Order Forum commissioned NIPH to perform a single-technology assessment of sutureless aortic valve replacement in the treatment of aortic stenosis. One company, Livanova, Sorin group, provided a submission file for a sutureless prosthetic heart valve (Perceval) (see details of the project here).

The report was dedicated to Perceval device in comparison to traditional aortic valve replacement for the treatment of operable patients with severe aortic stenosis in relation to efficacy, safety and cost-effectiveness. For this purpose, the systematic literature review was performed. No RCTs were identified within the search. Ten studies were comparative and ten studies were non-comparative. None of the studies reported quality of life data. The quality of the available evidence comparing Perceval sutureless aortic valve replacement to traditional aortic valve replacement is low to very low. More robust conclusions will be available upon publication of primary data from an ongoing RCT expected in 2019. Based on the cost-effectiveness and budget impact analyses submitted by the firm Perceval can be cost-saving compared to traditional sutured valves for an isolated full sternotomy or minimally invasive valve replacement surgery, and for concomitant surgeries with full sternotomy. Because the data used in the model were not based on the assessed comparative studies, there remains uncertainty about the likelihood and validity of the results. More robust conclusions will be possible on the publication of the ongoing RCT.

In September, the Decision Forum considered aortic valve replacement using Perceval as the suitable procedure for inclusion in the specialist health service. It was also stated that there is no evidence that sutureless prosthetic aortic valves differ significantly from the prosthetic valves that are already in use in terms of quality, safety and cost-effectiveness.

 

Digital breast tomosynthesis

In January 2016, the Order Forum commissioned NIPH to perform single technology appraisal for 3D digital breast tomosynthesis (DBT) in screening for breast cancer (see details of the project here).

In September of 2017, the NIPH published the report of the assessment of efficacy, safety and cost-effectiveness (see the full report here). There are several manufacturers of DBT systems, but only Hologic Inc., has submitted a documentation pack. In accordance with results of assessment, there is too little evidence to conclude regarding the effects of the use of Hologic digital breast tomosynthesis in combination with digital mammography or synthesized digital mammography compared to digital mammography alone. Introducing the Hologic Selenia Dimensions DBT-system can allow increasing the rate of screening-detected cancer. In the same time, it was evaluated that implementation of this system into the Norwegian Breast Cancer Screening Programme (NBCSP) will result in an increased radiation dose followed by an increased risk of radiation-induced cancer compared to the current practice with digital mammography. Additionally, DBT could be cost-effective. However, the budget impact analysis showed an increase in expenditure in 5 years after implementation of the procedure.

Therefore, on the meeting in September 2017, the Decision Forum did not recommend 3D digital breast tomosynthesis for routine breast cancer screening in the specialist health service.

See the list of releases decisions in September in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

Related news

03

May 2018

In April of 2018, the National Board of Health and Welfare (Socialstyrelsen) has published a report “Screening for severe combined immune deficiency”, which contains recommendation and assessment basis for the national combined immunodeficiency screening program (SCID).

Read more

26

Apr 2018

In mid-April 2018, the Galician HTA body, Avalia-T, has published a rapid evaluation report on screening of fetal trisomies 21, 18 and 13 by non-invasive prenatal testing. The report was done within EUnetHTA framework.

Read more

24

Apr 2018

The report “Development Trend 2018” will help to provide a basis for analyzing the environment for eHealth and creating a frame of reference for understanding the eHealth development.

Read more

17

Apr 2018

The Institute for Quality and Efficiency in Health Care (IQWiG) has selected four out of 31 themes for the future health technology assessments, which were proposed by the citizens at the web-site of ThemenCheck Medizin service and will presumably be published at the beginning of 2019. The next process of topics’ selection will start in August of 2018.

Read more

30

Mar 2018

The Clinical Coding and Schedule Development Group develops and maintains procedural and diagnostics nomenclature for private payers in England. In February new codes for genetic tests and immunological tests for infections were added to the CCSD Schedule.

Read more

09

Mar 2018

According to the recommendation of the National Board of Health and Welfare (Socialstyrelsen), hospitals and clinics should not offer screening for prostate cancer with PSA tests with or without other supplementary tests before tissue sampling. The recommendation is based on that the benefit of screening for prostate cancer with PSA tests does not outweigh the negative effects on a population level.

Read more

23

Feb 2018

The Danish National Board of Health has published a revised recommendation for how reception and status monitoring should be carried out on major x-ray devices for teeth examinations. The recommendation elaborates on previous requirements and contains suggestions for new measurement methods.

Read more

15

Feb 2018

The Clinical Coding and Schedule Development Group develops and maintains procedural and diagnostics nomenclature for private payers in England. In January new codes for Anti C1Q antibodies, soluble CD25, umbilical Cord Ph Level and several genetic tests were added to the CCSD Schedule.

Read more

02

Feb 2018

Ninety-two new codes have been implemented, including protein fractions and reproductive medicine tests.

Read more

30

Jan 2018

Applications for creation of new codes, removal of code or changes to existing codes and code description can be submitted by the Norwegian Directorate of Health.

Read more

23

Jan 2018

In the first half of January, the National Institute for Health and Care Excellence (NICE) published five new Medtech innovation briefings for in vitro diagnostic test for determining breast cancer subtypes, point-of-care creatinine tests before contrast-enhanced imaging, plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer, smartphone otoscope and sequencing panel for solid tumour cancers in children .

Read more

19

Jan 2018

The Clinical Coding and Schedule Development Group develops and maintains procedural and diagnostics nomenclature for private payers in England. In November new codes for allergy diagnostics, diagnostic profiles for certain diseases and detection of antibodies against Chlamydia were added to the CCSD Schedule.

Read more

17

Jan 2018

Since January 1, 2018, responsibility for managing the product regulations for medical devices is transferred from the Norwegian Directorate of Health to the Norwegian Medicines Agency.

Read more

16

Jan 2018

The program will cover the period of 2018-2025 and will focus on improvement of provision of health care services, introduction of innovations and other aspects of health care system. Overall budget of the program is 4.7 bln. euros. The program can create a window of opportunity for financing of innovative equipment and devices in Russia.

Read more

04

Jan 2018

The National Board of Health has not updated recommendations for cervical cancer screening since 2012. New evidence has been obtained for the detection of HPV infection as a screening method instead of or as a supplement to microscopic examination of cervical cells, and several countries plan to rearrange their screening programs.

Read more

03

Jan 2018

The current guideline replaces the previous version of the document of 2010. The Norwegian Directorate of Health decided to update the guideline because new methods of treatment and rehabilitation of stroke became avaliable in recent years.

Read more

23

Nov 2017

In the first half of November, the National Institute for Health and Care Excellence (NICE) published two new interventional procedures guidance (for total distal radioulnar joint replacement in symptomatic joint instability or arthritis and extracranial to intracranial bypass in intracranial atherosclerosis), one new diagnostics guidance for tests to identify people at high risk of ovarian cancer and four new Medtech innovation briefings.

Read more

14

Nov 2017

Patients should not pay anything other than regulated out-of-pocket payments when they visit general practitioner or other healthcare professional, who have contract with public health authorities.

Read more

13

Nov 2017

The Clinical Coding and Schedule Development Group develops and maintains procedural and diagnostics nomenclature for private payers in England. New codes were added for nitrogen washout test for lung capacity and fractional flow reserve CT measurement.

Read more

31

Oct 2017

Following the request of a patient organization, the Joint Federal Committee (G-BA) evaluated the newborn screening for tyrosinemia type I by tandem mass spectrometry and decided to include the method into the relevant guideline. Before the method can be applied and reimbursed in the statutory health insurance (SHI) in Germany, the Genetic Diagnostics Act requires approval by the Genetic Diagnostics Commission (GEKO).

Read more

24

Oct 2017

In June of 2017, the Ordering Forum RHF commissioned rapid method assessment for the Prosigna test. Only when the Norwegian Institute of Public Health receives documentation from the suppliers they carry out a quick method assessment. On 16th of the October, suppliers were requested to submit data to the Norwegian Institute of Public Health (NIPH) regarding clinical efficacy, safety and economics of Prosigna test.

Read more

12

Oct 2017

Irreversible electroporation (IRE) is a new minimally invasive method for the ablation of tumors. Currently, this method is not used in Norway. The conclusion of mini-HTA stated that IRE should be included as part of the routine clinical practice in the hospital.

Read more

06

Oct 2017

The Joint Federal Committee (G-BA) resumes assessments of methods that have been intermitted due to missing evidence: LDR brachytherapy in localized prostate carcinoma and PET or PET/CT for malignant lymphomas as well as for interim staging in Hodgkin's lymphoma. Studies conducted in the meantime are expected to provide sufficient evidence base for the assessment about the inclusion of the methods into the social health insurance benefit catalogue in Germany.

Read more

03

Oct 2017

New procedure codes will be created for stem cell procedures, extracorporeal techniques (including hemodialysis and CO2 removal), surgical interventions, including growth-controlling spinal correction, transposition of peripheral nerve, interventions on veins, and percutaneous image-guided procedures (including code for pressure measurement in coronary arteries and additional code for drug-eluting balloon). Classification will be enabled from January 1, 2018.

Read more

27

Sep 2017

The Clinical Coding and Schedule Development Group develops and maintains procedural and diagnostics nomenclature for private payers in England. New diagnostic codes cover different indications and analytical methods.

Read more

25

Sep 2017

Ministry of Health will close applications for proposals for inclusion of novel innovative tests into the List of Acts Outside Nomenclature in 2018 (Référentiel des actes Innovants Hors Nomenclatures, RIHN) 3rd of October 2017. RIHN provides early reimbursement for innovative tests, for which value is not yet validated to allow enlisting in the NABM Nomenclature.

Read more

19

Sep 2017

NHS Improvement together with providers of pathology (laboratory) services in England determined ways to integrate laboratory services to increase efficiency and reduce cost. The final proposal includes integration of pathology services of 105 English hospitals into 29 pathology networks, which would save NHS up to £200m annually.

Read more

08

Sep 2017

All significant innovations in Norway should undergo either national or hospital-based health technology assessment within “New Methods” framework. Guiding criteria for prioritization of topics for assessments were recently formulated by the administration of the program.

Read more

16

Aug 2017

In the second two weeks of July, the National Institute for Health and Care Excellence published one new (FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary care) and 3 updated Medtech Innovation Briefings, new Diagnostics Guidance for quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care and three new Interventional Procedures Guidance for laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease, transcatheter aortic valve implantation for aortic stenosis and hysteroscopic sterilisation by insertion of intrafallopian implants.

Read more

15

Aug 2017

European Network for health technology assessment (EUnetHTA) is initiating a project on assessment of screening of fetal aneuploidies (trisomy 13, 18 and 21) using non-invasive prenatal test (NIPT) in collaboration with Galician Agency for Health Technology Assessment (AVALIA-T) and Italian HTA agency Regione Emilia-Romagna. Completion of the project is planned to be on 30th of January, 2018 and aimed to evaluate effectiveness and safety of prenatal screening with NIPT, and also to assess organizational, ethical, legal issues and patient outcomes associated with this procedure.

Read more

09

Aug 2017

Changes will be made in eleven chapters of Nomenclature. In relation to medical technologies and in-vitro diagnostics, the most important changes include changes in conditions for Stomatology, Radiotherapy and Nuclear Medicine codes, introduction of new codes for IVD tests, including diagnostics of tuberculosis and screening for EGFR mutation.

Read more

03

Aug 2017

The Clinical Coding and Schedule Development Group develops and maintains procedural and diagnostics nomenclature for private payers in England. Several codes were added to both procedural and diagnostic Schedules, including procedures for treatment of knee and hip osteoarthritis, robotic procedure, insertion of wireless pacemaker.

Read more

24

Jul 2017

Hofmann and Gilbert published article exploring potential value of four novel diagnostic tests for clinicians: immunosignature for cancer and infections, breath test for lung cancer, patch vital sign monitoring and biomarkers for Alzheimer’s disease.

Read more

19

Jul 2017

Researchers evaluated care process, access, administrative efficiency, equity and health care outcomes in 11 countries on the basis of published health care statistics for 72 indicators. The best overall performers among European countries were the UK (ranked 1st), the Netherlands (3rd), Norway (4th), Sweden and Switzerland (6th). Germany (8th) and France (10th) were low in the ranking.

Read more

17

Jul 2017

The NIP test is a non-invasive prenatal test aimed at detecting Down's syndrome in fetus. This test is a screening performed using mother's blood sample from the 12th week of pregnancy. From 1 July 2017, non-invasive prenatal test will be reimbursed for all pregnant women.

Read more

05

Jul 2017

The guideline is based on recently updated and summarized research-based knowledge of the effects and side effects associated with the treatment. Both user experiences and research-based knowledge are emphasized in the assessments of the adverse effects that have been associated with the treatment.

Read more

27

Jun 2017

Assessments were directed by national HTA body AGENAS. They cover renal denervation for hypertension, next generation sequencing in oncology, robotic surgery, sling operation for urinary incontinence and vertebral disc replacement.

Read more

23

Jun 2017

An assessment was initiated earlier this year on the request from Dutch Hypertension Society and umbrella organization of 9 health insurance companies Zorgverzekeraars Nederland. The Institute will evaluate compliance of baroreflex activation therapy (BAT) for treatment of resistant hypertension with the state of science and practice.

Read more

12

Jun 2017

The Ministry of Health and Care Services has decided to transfer management tasks related to the medical device area from Norwegian Directorate of Health to the Norwegian Medicines Agency from 1 January 2018.

Read more

09

Jun 2017

Eleven national population screening programmes are implemented in the NHS on the advice of the UK National Screening Committee (UK NSC), which makes independent, evidence-based recommendations to ministers in the 4 UK countries. The Screening Quality Assurance Service ensures programmes are safe and effective by checking that national standards are met. Changes in 2017 are related to KPIs for bowel, breast, and cervical cancer screening.

Read more

08

Jun 2017

Administrators of the “New Method” program, which is focused on managed introduction of innovations into Norwegian system, have initiated technology assessments of 10 technologies and now have requested manufacturers to make submission of clinical and economic evidence.

Read more

16

May 2017

Changes will be made in nine chapters of Nomenclature. In relation to medical technologies and in-vitro diagnostics, the most important changes include changes in conditions for two ophthalmology and endoscopy codes, new conditions for reimbursement of photodynamic therapy in dermatology, introduction of two new codes for IVDs, and creating of requirements for reimbursement of number of IVD tests in pregnancy.

Read more

09

May 2017

Ludwig Boltzmann Institute - HTA conducted a budget impact analysis on request from the Federal Ministry of Health and Women (BMGF) for testing of TSH as screening for hypothyroidism, urine culture as screening for asymptomatic bacteriuria and ultrasound screening for foetal anomalies.

Read more

04

May 2017

Currently there are 10 ongoing mini-health technology assessments of medical technologies in Norway. After completion of evaluation, decision will be made about funding of these technologies at hospital level.

Read more

03

May 2017

Guidelines from Norwegian Directorate for Health have high impact and can be considered as commissioning guidelines. New criteria for screening for gestational diabetes and new fasting glucose threshold for diagnosis were determined.

Read more

02

May 2017

The Forum of Norwegian payers made decision about introduction of three medical technologies: mechanical thrombectomy for stroke, baroreflex activation therapy for resistant hypertension and non-invasive prenatal testing for detection of trisomy 13, 18 and 21.

Read more

28

Apr 2017

Three mini-HTAs were published since beginning of 2017: procalcitonin for diagnostic of bacterial infections, Per Oral Endoscopic Myotomy (POEM) for achalasia, and use of the Prosigna test (PAM50 ROR) for decisions on adjuvant treatment in breast cancer. These assessments can support introduction of methods at local hospital level in Norway.

Read more